Lind Kevin Robert 4

What Happened

• Kevin Robert Lind, a director of Avalo Therapeutics, received a derivative award on June 30, 2026 covering 1,105 shares with a reported per-share price of $15.04 (total reported value $16,619). The award is described in the filing as a grant/award (derivative security).

Key Details

• Transaction date: 2026-06-30; reported filing date: 2026-07-02 (filed within typical Form 4 timing).
• Security/amount: derivative award/options covering 1,105 shares at $15.04 per share; total reported value $16,619.
• Vesting: Footnote states the options were granted on June 30, 2026 and are 100% vested (can be exercised immediately subject to plan terms).
• Shares owned after transaction: Not specified in the provided Form 4 details.
• Transaction code: A (award/grant/acquisition); no sale or exercise reported in this filing.

Context

• This was an award of derivative securities (options) rather than an open-market purchase or sale. Because the grant is 100% vested, the director may exercise the options now, but the filing does not show any exercise or sale.
• Grants to directors are a common form of compensation to align interests with shareholders; they are informative about compensation but do not, by themselves, indicate the director’s intent to buy or sell shares.